TScan Therapeutics (TCRX) Return on Sales (2020 - 2025)
Historic Return on Sales for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 14.22%.
- TScan Therapeutics' Return on Sales rose 142700.0% to 14.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.8%, marking a year-over-year decrease of 49100.0%. This contributed to the annual value of 44.89% for FY2024, which is 406500.0% down from last year.
- According to the latest figures from Q3 2025, TScan Therapeutics' Return on Sales is 14.22%, which was up 142700.0% from 12.01% recorded in Q2 2025.
- Over the past 5 years, TScan Therapeutics' Return on Sales peaked at 2.72% during Q4 2023, and registered a low of 59.07% during Q2 2024.
- Its 5-year average for Return on Sales is 15.49%, with a median of 6.05% in 2022.
- Its Return on Sales has fluctuated over the past 5 years, first tumbled by -514300bps in 2024, then surged by 470600bps in 2025.
- TScan Therapeutics' Return on Sales (Quarter) stood at 4.98% in 2021, then fell by -22bps to 6.05% in 2022, then skyrocketed by 55bps to 2.72% in 2023, then crashed by -1820bps to 52.21% in 2024, then surged by 73bps to 14.22% in 2025.
- Its last three reported values are 14.22% in Q3 2025, 12.01% for Q2 2025, and 15.72% during Q1 2025.